重组人类促红细胞生成素防治早产儿贫血的临床分析  

Evaluation of clinical efficacy of domestic made recombinant human erythropoietin in preventing and treating anemia in preterm infants

作　　者：刘平[1] 郭芳[1] 朱进秋[1] 谢晓玲[1] 

机构地区：[1]昆明市妇幼保健院新生儿科,云南昆明650031

出　　处：《云南医药》2005年第3期219-220,共2页Medicine and Pharmacy of Yunnan

摘　　要：Objective To evaluate the efficacy of erythropoietin in prevention and treatment of anemia of prematurity. Methods 119 preterm infants were randomly assigned to receive (treated group,60 neonates) or not to receive(control group, 59 neonates) rhEPO. RhEPO (750IU·kg -1·w -1)was given three times weekly for 4 weeks.Both these two groups received iron and folic acid.Results Treated group had a marked increase of reticulocyte compared with the control group (P<0.01).There were statistically significant differences between these two groups in the rate of weight gain(P<0.05).Condusion Early administration of high dosage of rhEPO can lighten the degree of anemia inObjective To evaluate the efficacy of erythropoietin in prevention and treatment of anemia of prematurity. Methods 119 preterm infants were randomly assigned to receive (treated group,60 neonates) or not to receive(control group, 59 neonates) rhEPO. RhEPO (750IU·kg -1·w -1)was given three times weekly for 4 weeks.Both these two groups received iron and folic acid.Results Treated group had a marked increase of reticulocyte compared with the control group (P<0.01).There were statistically significant differences between these two groups in the rate of weight gain(P<0.05).Condusion Early administration of high dosage of rhEPO can lighten the degree of anemia in neonate

关 键 词：促红细胞生成素 早产儿 贫血 

分 类 号：R722.6[医药卫生—儿科]